Click here for slides on this topic


Creatinine

A waste product derived from the activity of the muscles that is normally excreted by the kidneys. Excess creatinine in the blood signals that the kidneys are losing their ability to function normally.
The following content matched the glossary term: Creatinine

Treating the Patient With Type 2 Diabetes and Renal Impairment – References

Top

Patient case: 58-Year-Old African-American Woman with Type 2 Diabetes, Worsening Kidney Function, and Cardiometabolic Comorbidities  

Presented by NDEI Education Council Member, Vivian A. Fonseca, MD

 

Treating the Patient With Type 2 Diabetes and Renal Impairment – Key Take-Home Messages

Top

Patient case: 58-Year-Old African-American Woman with Type 2 Diabetes, Worsening Kidney Function, and Cardiometabolic Comorbidities

Presented by NDEI Education Council Member, Vivian A. Fonseca, MD

 

Treating the Patient With Type 2 Diabetes and Renal Impairment – Follow-Up Pharmacologic Therapy Considerations Proteinuria

Top

Patient case: 58-Year-Old African-American Woman with Type 2 Diabetes, Worsening Kidney Function, and Cardiometabolic Comorbidities  

Presented by NDEI Education Council Member, Vivian A. Fonseca, MD

 

Treating the Patient With Type 2 Diabetes and Renal Impairment – Follow-Up Pharmacologic Therapy Considerations Metformin

Top

Patient case: 58-Year-Old African-American Woman with Type 2 Diabetes, Worsening Kidney Function, and Cardiometabolic Comorbidities  

Presented by NDEI Education Council Member, Vivian A. Fonseca, MD

 

Treating the Patient With Type 2 Diabetes and Renal Impairment – Follow-Up

Top

Patient case: 58-Year-Old African-American Woman with Type 2 Diabetes, Worsening Kidney Function, and Cardiometabolic Comorbidities  

Presented by NDEI Education Council Member, Vivian A. Fonseca, MD

 

Treating the Patient With Type 2 Diabetes and Renal Impairment – Case Discussion Pharmacologic Treatment for Type 2 Diabetes

Top

Patient case: 58-Year-Old African-American Woman with Type 2 Diabetes, Worsening Kidney Function, and Cardiometabolic Comorbidities  

Presented by NDEI Education Council Member, Vivian A. Fonseca, MD

 

Treating the Patient With Type 2 Diabetes and Renal Impairment – Case Discussion Hypoglycemia

Top

Patient case: 58-Year-Old African-American Woman with Type 2 Diabetes, Worsening Kidney Function, and Cardiometabolic Comorbidities  

Presented by NDEI Education Council Member, Vivian A. Fonseca, MD

 

Treating the Patient With Type 2 Diabetes and Renal Impairment – Case Discussion Treatment Adjustment for Renal Impairment

Top

Patient case: 58-Year-Old African-American Woman with Type 2 Diabetes, Worsening Kidney Function, and Cardiometabolic Comorbidities  

Presented by NDEI Education Council Member, Vivian A. Fonseca, MD

 

Treating the Patient With Type 2 Diabetes and Renal Impairment – Case Discussion Renal Impairment

Top

Patient case: 58-Year-Old African-American Woman with Type 2 Diabetes, Worsening Kidney Function, and Cardiometabolic Comorbidities  

Presented by NDEI Education Council Member, Vivian A. Fonseca, MD

 

Treating the Patient With Type 2 Diabetes and Renal Impairment – Medical History Physical Exam

Top

Patient case: 58-Year-Old African-American Woman with Type 2 Diabetes, Worsening Kidney Function, and Cardiometabolic Comorbidities  

Presented by NDEI Education Council Member, Vivian A. Fonseca, MD

 

1 2 3 4 5 Next 

Slide Library Results

Search Results for: Creatinine Slides Found: 38
RENAAL: Impact of Losartan in Chronic Kidney Disease
Microalbuminuria Predicts CV Risk at Levels Below Current Definition
CALM: Renoprotection With Candesartan vs Lisinopril in Type 2 Diabetes
Impact of Higher Heart Rate on Development of Cardiometabolic Risk Factors After 20 Years
ACCORD BP: Effects of Intensive BP-Control on Type 2 Diabetes
ACCORD Substudy: Impact of Frequent and Unrecognized Hypoglycemia on Mortality—Design
Saxagliptin for Treatment of Subjects with Type 2 Diabetes and Renal Impairment: Design
Saxagliptin for Treatment of Subjects with Type 2 Diabetes and Renal Impairment: Change in A1C from Baseline to Week 52
Saxagliptin for Treatment of Subjects with Type 2 Diabetes and Renal Impairment: Additional Results
ORIGIN Omega-3 Fatty Acid Trial: Eligibility Criteria and Trial Profile
ORIGIN Omega-3 Fatty Acid Trial: Baseline Characteristics (1 of 2)
ORIGIN Omega-3 Fatty Acid Trial: Baseline Characteristics (2 of 2)
ADA/AGS 2012 Consensus Report on Diabetes in Older Adults: Recommendations for Care and Treatment (2 of 3)
ADVANCE Post-hoc Analysis: Low HDL-C and Microvascular Event Risk
Diurnal Pattern to Insulin Action in Type 1 Diabetes: Design
Canagliflozin: Renal Considerations
ACCORD: Factors Associated with Increased Hypoglycemia Risk in Intensive and Standard Treatment Arms
ALTITUDE: No Reduction in CV, Renal Events with Aliskiren
Intensive Statin Therapy and Adverse Events: Meta-Analysis
Metformin: Renal Considerations
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Secondary Prevention: Age 75 Years or Younger
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Secondary Prevention: Age 75 and Older
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Primary ASCVD Prevention: Age 40-75 With Diabetes or LDL 190 or Higher
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Primary ASCVD Prevention: Age 40-75, LDL 70-189, No Diabetes
ACC/AHA Cholesterol Guidelines 2013: Statin Safety Recommendations: CK & ALT
ACC/AHA Cholesterol Guidelines 2013: Statin Safety Recommendations: Muscle Symptoms
Type 2 Diabetes Treatment Intensification Albuminuria | NDEI
IDF Type 2 Diabetes Guidelines Kidney Disease | NDEI
IDF Type 2 Diabetes Guidelines Neuropathy | NDEI
Diabetes Pregnancy Guidelines Renal Nephropathy | NDEI
Edinburgh Type 2 Diabetes Study Severe Hypoglycemia Slide PPT | NDEI
RYGB Vs Sleeve Gastrectomy for Weight Loss & Glycemic Control ENDO2015 | NDEI
AACE 2015 Diabetes Guidelines Nephropathy Management Microvascular | NDEI
ELIXA Cardiovascular Safety Outcomes for Lixisenatide GLP-1 | NDEI
ADA Guidelines Treating Microvascular Complications in Children With Type 1 Diabetes | NDEI
GAUSS-3 Muscle-Related Adverse Events With Evolocumab & Ezetimibe | NDEI
ASCVD Risk Assessment Algorithm NLA Cholesterol Guidelines | CCMD
Empagliflozin Renal Outcomes in EMPA-REG OUTCOME CVOT | NDEI